The underlying neurodegenerative process that causes Parkinson disease (PD) begins decades before the disease is diagnosed.^[@R1]^ The current view is that following an initial insult (e.g., toxicity, trauma, or genetic), the disease starts with an asymptomatic phase of unknown duration, followed by development of prodromal nonmotor symptoms such as constipation, anosmia, and sleep disorders. Years later, cardinal motor signs appear, at which point a diagnosis of PD is made. Age at onset of motor signs, and therefore the age at diagnosis of PD, is highly variable, ranging from teen ages to the 10th decade of life. The reason for this variation is unknown, and understanding it will likely shed light on factors that affect the rate of disease progression.

There is substantial evidence that genetic factors play a major role in age at onset of motor signs and age at diagnosis of PD.^[@R2][@R3][@R6]^ Genome-wide studies have identified numerous loci that associate with the risk of developing PD,^[@R7]^ but the risk factors do not explain the variation in age at onset.^[@R8][@R9][@R10]^ Three loci have been nominated as modifiers of age at onset in familial PD.^[@R11],[@R12]^ The present study was aimed at identifying genetic modifiers for common idiopathic PD. We hypothesized that identification of the genetic basis to interindividual variability in age at diagnosis will provide insights into the intrinsic mechanisms that determine the rate of deterioration during preclinical disease.

Methods {#s1}
=======

This study was a case-control GWAS, followed by replication and functional annotation.

Standard protocol approvals, registrations, and patient consents {#s1-1}
----------------------------------------------------------------

The study was approved by the institutional review boards at all participating institutions. Written informed consent was obtained from all patients and controls for participation in the study.

Participants {#s1-2}
------------

The study included 2 data sets. The NeuroGenetics Research Consortium (NGRC) data set^[@R13]^ was used for the discovery GWAS, gene-based test, and functional annotations. The Parkinson\'s, Genes and Environment (PAGE) study^[@R14]^ was used for replication. Participants\' characteristics are shown in [table 1](#T1){ref-type="table"} and figure e-1 ([links.lww.com/NXG/A66](http://links.lww.com/NXG/A66)).

###### 

Data sets and participants\' characteristics
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NGRC is a case-control study of genetically unrelated participants, including 2000 PD cases and 1986 controls.^[@R13]^ Patients were enrolled sequentially from movement disorder clinics in Portland (OR), Seattle (WA), Albany (NY), and Atlanta (GA). Controls were spouses of patients or community volunteers, self-reported as being free of neurologic disease. The eligibility criterion for cases was diagnosis of PD by a movement disorder specialist according to the UK Brain Bank criteria.^[@R15]^ The eligibility criteria for controls were no neurologic disease and genetically unrelated to patients. Age was defined as age at study entry. Age at diagnosis was extracted from medical records or ascertained by self-report. Age at onset of the first motor sign was obtained using a self-administered questionnaire. Age at onset and age at diagnosis were highly correlated in the NGRC (*r*^2^ = 0.91, *p* \< 2E-16). All participants were whites of European descent.^[@R13]^

PAGE is a cross-sectional study nested in the longitudinal NIH-American Association of Retired Persons Diet and Health Study.^[@R14]^ Participants were enrolled in 1995--1997 (irrespective of PD) via a food frequency questionnaire mailing^[@R16]^ and in the 2004--2006 follow-up visit were asked if they had been diagnosed with a major chronic disease including PD. Participants who had been diagnosed with PD before enrollment (before 1998) were designated as prevalent PD (PAGE~P~, N = 209), participants who were diagnosed during follow-up (1998--2006) were designated as incident PD (PAGE~I~, N = 517), and participants who did not have PD were designated as controls (N = 1,549). All participants in this study were non-Hispanic whites.

Genotyping {#s1-3}
----------

NGRC participants were genotyped on Illumina HumanOmni1-Quad v1-0 B array and Immunochip array. Genotypes and samples were filtered by call rate, minor allele frequency (MAF) \< 0.01, Hardy-Weinberg, and cryptic relatedness, as described before.^[@R13]^ Imputation was performed using IMPUTE v2.3.0,^[@R17]^ with the 1000G Phase3 integrated variant set (October 2014) as reference. Imputed single nucleotide polymorphisms (SNPs) with info score \< 0.9 or MAF \< 0.01 were excluded. A total of 8.5 million SNPs (900,000 genotyped and 7.6 million imputed) were used in the analysis.

PAGE participants were genotyped for rs73656147 (block 1) and rs17763929 (block 2). SNPs were chosen based on statistical significance and availability of predesigned validated TaqMan assay from Thermo Fisher (rs73656147 assay number = C\_\_97534229_10; rs17763929 assay number = C\_\_34297681_10).

Population structure {#s1-4}
--------------------

Principal component (PC) analysis^[@R18]^ is used to infer population-specific genetic differences, which arise from ancestry differences in allele frequencies and can obscure genetic association studies if not accounted for. NGRC PC analysis was conducted using a pruned subset of 100K SNPs from the GWAS as previously described.^[@R13]^ The top 3 PCs (effect sizes PC1 = 0.2%, PC2 = 0.06%, and PC3 = 0.06%) were included in the GWAS and adjusted for in all downstream analyses involving the NGRC. The PAGE data sets used for replication did not have ancestry informative markers (AIMs); however, a subset of the participants (396 of 726 PD cases) was previously genotyped with the Immunochip array. We conducted PC analysis using a pruned set of 20K SNPs from the Immunochip array, using PLINK. Tests were conducted once using the full PAGE data set, with no PC adjustment, and again with a PAGE subset, adjusting for PC1-3 (effect sizes PC1 = 0.48%, PC2 = 0.20%, and PC3 = 0.17%). NGRC and PAGE cluster with Europeans in the 1000G_Phase_3 global data set (figure e-2, [links.lww.com/NXG/A67](http://links.lww.com/NXG/A67)).

Statistics {#s1-5}
----------

### Discovery {#s1-5-1}

GWAS was conducted using PD cases only (1,950 NGRC participants with known age at diagnosis). Association between 8.5M SNPs and age at diagnosis was tested using Cox regression in ProbABEL v0.5.0.,^[@R19]^ specifying an additive genetic model, treating age at diagnosis as a quantitative trait, and adjusting for PC1-3. The statistical outcome of Cox regression was hazard ratios (HRs) and corresponding *p* values. Statistical significance was set at *p* \< 5E-8. Manhattan plots and quantile-quantile (QQ) plots were generated using FUMA v1.3.0.^[@R20]^ Genomic inflation factor (λ) was calculated using the estlambda function in GenABEL v1.8 in R.^[@R21]^ LocusZoom^[@R22]^ was used to visualize the chr9:103,865,000--104,055,000 region (GWAS peak). Haploview v4.2^[@R23]^ was used to generate linkage disequilibrium (LD) plots of D′ and r^2^ for SNPs in the chr9:103,865,000--104,055,000 region with GWAS *p* \< 1E-4. LD between 2 SNPs was calculated using 1000G Phase3 v5 in LDlink.^[@R24]^ Linear regression was used to estimate and test differences in mean age at diagnosis (β). Conditional analysis was performed using coxph function in the survival v2.41 R package. Moving average plots (MAPs) were generated using the freqMAP v0.2 R package.^[@R25]^

Gene-based analysis was conducted using summary statistics from the GWAS and LD from the 1000G Phase3 EUR to map the GWAS SNPs to 18,985 protein-coding genes (hg19 build) and to calculate gene-based *p* values, using MAGMA v1.06,^[@R26]^ as implemented in FUMA v1.3.0.^[@R20]^ Statistical significance was set at Bonferroni-corrected *p* \< 2.6E-6 (0.05/18,985).

### Replication {#s1-5-2}

Cox regression (coxph function in the survival v2.41 R package) was used to replicate the association of 2 SNPs with age at diagnosis. We used the same model as the NGRC (additive genetic model, treating age at diagnosis as a quantitative trait). Because of the availability of PCs only in a subset of PAGE, analyses were conducted twice: using the full PAGE data set without PC adjustment and using the subset that had AIMs and adjusting for PC1-3. PAGE~I~ and PAGE~P~ were treated separately and were combined using meta-analysis after testing for heterogeneity. If *p* of heterogeneity was \<0.1, the fixed-effect model was used. Meta-analysis was performed using the metagen function in the meta v4.8 R package.

Functional annotation {#s1-6}
---------------------

Functional annotation was conducted in FUMA v1.3.0,^[@R20]^ using SNPs with GWAS *p* \< 1E-6 and all variants in *r*^2^ ≥ 0.6 with them, and included CADD analysis,^[@R27]^ eQTL mapping,^[@R28]^ 3D chromatin interaction mapping (Hi-C),^[@R29]^ annotation of enhancers,^[@R30]^ tissue-specific expression of genes identified via Hi-C and eQTL mapping,^[@R28]^ and their age-specific expression in the brain ([BrainSpan.org](http://BrainSpan.org)). The false discovery rate (FDR) was used to correct for multiple testing. STRUM was used to predict the effect of a missense on the structural stability of a protein.^[@R31]^

Data availability {#s1-7}
-----------------

NGRC genotype and phenotype data are available at dbGaP [ncbi.nlm.nih.gov/gap](https://www.ncbi.nlm.nih.gov/gap) accession number [phs000196.v3.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000196.v3.p1).

Results {#s2}
=======

GWAS {#s2-1}
----

In SNP-based GWAS, the most significant signal for association, at *p* = 5E-8, mapped to *LPPR1* on chromosome 9q31.1 ([figure 1, A and B](#F1){ref-type="fig"}). In the gene-based test, *LPPR1* achieved *p* = 1E-8, surpassing the genome-wide statistical significance threshold of *p* \< 2.6E-6 ([figure 1, C and D](#F1){ref-type="fig"}). The *p* values were not inflated (λ = 1.007 SNP based, λ = 1.04 gene based). Analysis of LD in the region revealed 2 haplotype blocks with seemingly independent signals for association ([figure 1, E and F](#F1){ref-type="fig"}). There was strong LD among SNPs in each block, but weak LD between the blocks (*r*^2^ ≤ 0.2) because of a recombination hot spot between them ([figure 1F](#F1){ref-type="fig"}). The 2 blocks were in a ∼200 Kb region inside *LPPR1*. Block 1 consisted of 51 SNPs with MAF∼0.01, which yielded HR = 2.02--1.88, with *p* = 9E-7 to 2E-5 for association with age at diagnosis. Block 2 consisted of 39 SNPs with MAF∼0.02, which yielded HR = 1.88--1.85, with *p* = 5E-8 to 7E-7. We chose 1 SNP to represent each block for replication: rs73656147 for block 1 (MAF = 0.01, HR = 1.95, *p* = 3E-6) and rs17763929 for block 2 (MAF = 0.02, HR = 1.88, *p* = 5E-8), both in Hardy-Weinberg (*p* \> 0.3), with little correlation between them (*r*^2^ = 0.2). Conditional analysis conducted to determine whether the 2 blocks were tagging the same or different disease-associated variants was inconclusive because although the signals were weakened when adjusted for each other, neither was abolished when conditioned on the other (table e-1, [links.lww.com/NXG/A69](http://links.lww.com/NXG/A69)).

![Results of genome-wide association study for age at diagnosis of PD\
Genome-wide association was tested between 8.5 million SNPs and age at diagnosis in 1,950 PD cases from the NGRC, using the Cox hazard ratio regression method and adjusting for principal components (PC1-3). (A) Manhattan plot of SNP-based GWAS. Tallest peak, at *p* = 5E-8, was on chromosome 9q31.1. (B) QQ plot of SNP-based GWAS. The observed *p* values were not inflated (λ = 1.007). (C) Manhattan plot of gene-based GWAS. *LPPR1* was at *p* = 1E-8. Statistical significance threshold was *p* \< 2.6E-6, which is Bonferroni corrected for the 18,985 protein-coding genes tested. (D) QQ plot of gene-based GWAS. The observed *p* values were not inflated (λ = 1.04). (E) *r*^2^ (top panel) and D\' (bottom panel). Linkage disequilibrium (LD) across the SNPs that gave *p* \< 1E-4 for association with age at diagnosis reveals 2 blocks represented by rs73656147 (left triangle) and rs17763929 (right triangle). (F) Magnified map of the associated region (chr9:103,865,000--104,055,000), showing that PD-associated SNPs map to *LPPR1* and form 2 haplotype blocks separated by recombination hot spots (blue spikes). (G) Chromatin state of *LPPR1* (Roadmap 111 Epigenomes), showing that active enhancers (yellow), transcription start site (red), and transcripts (green) of *LPPR1* are seen only in stem cells and the brain and that the GWAS SNPs align with regulatory elements. ESC = embryonic stem cell; iPSC = induced pluripotent stem cell; TssA = active transcription start site (TSS); TssAFlnk = flanking active TSS; TxFlnk = transcription at gene 5′ and 3\'; Tx = strong transcription; TxWk = weak transcription; EnhG = genic enhancers; Enh = enhancers; ZNF/Rpts = zinc-finger genes and repeats; Het = heterochromatin; TssBiv = bivalent/poised TSS; BivFlnk = flanking bivalent TSS/enhancer; EnhBiv = bivalent enhancer; ReprPC = repressed polycomb; ReprPCWk = weak repressed polyComb; Quies = quiescent.](NG2018007682FF1){#F1}

There are 2 caveats in interpreting statistical evidence for association with age at diagnosis. First, age at diagnosis is correlated with age (*r*^2^ = 0.74, *p* \< 2E-16), which can result in spurious conclusions if the driving force responsible for the association is not identified. Second, tests of age at diagnosis are conducted using patients only without the benefit of controls. For example, an SNP that appears to be associated with earlier PD diagnosis may in fact be associated with an age-related event unrelated to PD. To interpret the statistical evidence for association with age at diagnosis, we examined whether and how allele frequencies vary by age in cases or in controls. Allele frequencies were plotted in a moving average window as a function of age (figure e-3, [links.lww.com/NXG/A68](http://links.lww.com/NXG/A68)). Starting at age 45 years, allele frequencies were the same in cases and controls. In controls, allele frequencies remained the same across the age spectrum, whereas in cases, they decreased sharply and significantly by age and by age at diagnosis. The effect was therefore in cases and not in controls. Next, conditional analysis was conducted to tease age from age at diagnosis ([table 2](#T2){ref-type="table"}). The minor alleles of rs73656147 and rs17763929 were associated with age, as was expected, given their association with age at diagnosis. However, the association with age at diagnosis persisted when adjusted for age, but the association with age was abolished when adjusted for age at diagnosis. Hence, age at diagnosis was the driving force, and association with age was a by-product of the correlation.

###### 

Association of *LPPR1* variants with age and age at diagnosis is driven by age at diagnosis
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To gauge robustness of the association signals with age at diagnosis and to test for heterogeneity, we stratified the data by 8 PD-relevant variables, tested the association of each SNP with age at diagnosis within each stratum, and compared the results across strata for evidence of heterogeneity (table e-2, [links.lww.com/NXG/A70](http://links.lww.com/NXG/A70)). The 8 categories of stratification were family history, sex, cigarette smoking, caffeine intake, nonsteroidal anti-inflammatory drugs use, recruitment site, Jewish heritage, and the European country of ancestral origin. The association signal for rs73656147 (block 1) was robust across all strata. rs17763929 (block 2) showed evidence of heterogeneity as a function of recruitment site and the European country of ancestral origin. Given these results, we tested the association of the 2 SNPs with PCs. rs17763929 was associated with PC1 (*p* = 7E-6) and PC3 (*p* = 8E-3), and rs73656147 was not (*p* \> 0.05 for PC1-3), indicating the presence of population structure in block 2 but not in block 1.

Replication {#s2-2}
-----------

In comparison to NGRC, which had a 65-year range for age at diagnosis, the PAGE data sets had a narrower range of less than 30 years. Because PAGE participants were of similar age at study entry, the method of classifying the participants into prevalent PD (diagnosis before entry) vs incident PD (diagnosis after entry) inevitably assigned earlier ages at diagnosis to the prevalent group (PAGE~P~) and later diagnoses to the incident group (PAGE~I~). Mean age at diagnosis in PAGE~P~ was 59.9 ± 6.6 years, which was similar to the NGRC (60.4 ± 11.4). PAGE~I~ participants were on average 10 years older at diagnosis (69.4 ± 5.4, range 53--81 years). Given the disparity in the range and mean ages at diagnosis, we analyzed PAGE~P~ and PAGE~I~ separately.

Association of rs73656147 (block 1) with age at diagnosis replicated robustly ([table 3](#T3){ref-type="table"}). There was no evidence of heterogeneity between PAGE~I~ and PAGE~P~ in the association of rs73656147 with age at diagnosis, although the signal was stronger in PAGE~P~ than in PAGE~I~, which is not surprising, given that the former is enriched in cases with earlier age at diagnosis. Nor was there evidence of heterogeneity between PAGE and NGRC for the association of rs73656147 with age at diagnosis. Meta-analysis yielded HR = 2.14, *p* = 1E-3 for replication and HR = 2.00, *p* = 9E-9 for replication and discovery. Mean difference in age at diagnosis per copy of rs73656147 minor allele was −6.0 (95% confidence interval: −9.18 to −2.83) years in the NGRC, −5.53 (−9.72 to −1.34) in PAGE~P~, −0.84 (−4.22 to 2.55) in PAGE~I~, and −4.08 (−7.45 to −0.70) in the meta-analysis of the 3 data sets.

###### 

Replication
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Association of rs17763929 (block 2) with age at diagnosis showed significant heterogeneity between PAGE~I~ and PAGE~P~ ([table 3](#T3){ref-type="table"}), as it had within the NGRC (table e-2, [links.lww.com/NXG/A70](http://links.lww.com/NXG/A70)). The association with rs17763929 replicated in PAGE~P~ but not in PAGE~I~. There was significant heterogeneity between PAGE~I~ and NGRC, but not between PAGE~P~ and NGRC. Meta-analysis of PAGE~P~ and NGRC yielded HR = 1.88, *p* = 4E-9 for full PAGE data and HR = 1.95, *p* = 3E-9 for the PAGE subsample adjusted for PC1-3. Including PAGE~I~ with PAGE~P~ and NGRC in a random-effects meta-analysis diluted the effect size to HR = 1.53, *p* = 0.04. Mean difference in age at diagnosis per copy of rs17763929 minor allele was −5.65 (−8.20 to −3.11) years in the NGRC, −3.62 (−7.23 to −0.02) in PAGE~P~, and 0.62 (−1.34 to 2.58) in PAGE~I~.

Functional annotation {#s2-3}
---------------------

Hi-C analysis showed significant (FDR \< 1E-6) chromatin interaction between the PD-associated *LPPR1* SNPs and promoters of *LPPR1* and several genes on chromosome 9 ([figure 2, A](#F2){ref-type="fig"}). Some of the SNPs that were significant in Hi-C mapped to enhancers in the brain ([table 4](#T4){ref-type="table"} and [figure 1, G](#F1){ref-type="fig"}). Eleven of the genes identified through Hi-C are expressed in the brain: *LPPR1, SEC61B, MSANTD3-TMEFF1, TMEFF1, GALNT12, MURC, GRIN3A, NR4A3, ALG2, MRPL50,* and *ZNF189* ([figure 2, B and C](#F2){ref-type="fig"}). The expression of *LPPR1* in the brain is the strongest in early prenatal stage and decreases with developmental stage and increasing age ([figure 2, C](#F2){ref-type="fig"}).

![Functionally significant genes\
(A) 3D chromatin interaction (Hi-C) and eQTL analysis. Hi-C revealed significant interaction between GWAS variants in *LPPR1* and 17 other genes on chromosome 9 (FDR \< 1E-6, shown in orange). An SNP in *LPPR1* was associated with the expression of *GRIN3A* (FDR = 4E-4, shown in green). (B) Tissue-specific expression of *LPPR1, GRIN3A*, and genes in Hi-C with *LPPR1*. Colors reflect average expression (log2 transformed) from highest (red) to lowest/absent (blue). (C) Age-specific expression of the genes in the brain. *LPPR1* expression decreases with age.](NG2018007682FF2){#F2}

###### 

Functionally significant variants
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CADD analysis, a scoring system for deleteriousness of genetic variants, identified 5 SNPs in block 1 and 3 in block 2, with CADD = 10--19 ([table 4](#T4){ref-type="table"}), which places them among the top 10% (CADD \> 10) to 1% (CADD \> 20) of most deleterious mutations in the genome.^[@R27]^ rs41296085 (CADD = 18, in block 1) is a missense (p.Ser12Ala) in exon 2, predicted to structurally destabilize the LPPR1 protein (∆∆G = −1.2). The remainder of the variants with high CADD scores are in introns. eQTL analysis revealed an association between rs117451395 (block 1) with expression levels of *GRIN3A* (FDR = 4E-4).

Discussion {#s3}
==========

There has been intense research on PD risk factors, which so far has resulted in identification of numerous causative genes, 40 susceptibility loci, several environmental factors, and a few genes that interact with the environmental factors to increase or reduce the risk of developing PD. In contrast, we know little about factors that affect the rate of disease progression. In this study, we attempted to identify genetic modifiers of age at diagnosis, a reflection of rate of progression, using an unbiased genome-wide approach, followed by independent replication, and functional annotation.

We uncovered evidence for association of genetic variants in neuronal plasticity-related gene 3 (*LPPR1*) with age at diagnosis of PD. Two signals of association were detected, each representing a haplotype block of SNPs. The variants that were associated with earlier age at diagnosis had low allele frequencies (MAF = 0.01--0.02), as were the variants that were previously found for age at onset of familial PD.^[@R11]^ The low allele frequencies may be one reason why modifier genes have been more difficult to detect than common variants that associate with risk.

The association with block 1 replicated robustly in both PAGE~P~ and PAGE~I~. Block 2 signal replicated in PAGE~P~ but not in PAGE~I~. Block 2 has a complex LD structure, with evidence of population substructure, which limits generalizability of results. Failure to capture a signal for block 2 in PAGE~I~ may be because we had genotype on only 1 SNP in block 2 for PAGE, which did not fully capture the complexity of block 2. PAGE~I~ participants being significantly older than NGRC and PAGE~P~ participants may also be a factor. *LPPR1* promotes neuroregeneration,^[@R32][@R33][@R34]^ but its expression diminishes with age to nearly undetectable level by age 40 years ([figure 2C](#F2){ref-type="fig"}). One can speculate that some detrimental variants may not have an effect after a certain age when the gene is no longer expressed.

Functional annotation of the PD-associated variants in *LPPR1* revealed the presence of several variants with predicted deleterious effects, including a missense that destabilizes the structure of LPPR1, a regulatory element that associates with expression levels of *GRIN3A*, and enhancers that interact with promoters of *LPPR1* and several other genes in the brain. Some of the candidate genes that were identified via interaction with *LPPR1* play key roles in pathways that are implicated in PD, including *GRIN3A* (which encodes a subunit of NMDA receptor involved in the glutamate-regulated ion channels in the brain), *SEC61B* (protein transport apparatus of the endoplasmic reticulum membrane), *MURC* (Rho kinase signaling), and *MRPL50* (mitochondrial ribosomal protein).

*LPPR1* is one of the 5 members of a brain-specific gene family that modulates neuronal plasticity during development, aging, and after brain injury.^[@R32][@R33][@R34]^ *LPPR1* is the strongest driver of axonal outgrowth in the gene family. Studies in mice have shown that after neuronal injury, overexpression of *LPPR1* enhances axonal growth, improves motor behavior, and promotes functional recovery.^[@R33],[@R34]^ Extrapolating to our findings, we propose that *LPPR1* is involved, not necessarily in the cause of PD, rather in response to damage, and influences the efficacy of regeneration and the subsequent rate of deterioration in preclinical PD. The actual cause of injury and neuronal death is not stipulated in this hypothesis; it could be head trauma, environmental toxins or genetic, but once the initial damage is incurred, it is the efficacy of intrinsic mechanisms of repair that determine the rate of disease progression. Present findings provide a strong foundation for mechanistic studies to investigate the role of *LPPR1* in PD and determine its potential as a therapeutic target to impede disease progression.
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